This is a rare type of cancer that starts in the follicular dendritic cells, which are part of the immune system. It usually develops in the lymph nodes and is more common in adults.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Follicular dendritic cell sarcoma (FDCS) is a rare cancer that starts in follicular dendritic cells. These are support cells of the immune system that live inside lymph nodes, where they help other immune cells learn to recognize and make antibodies against germs. In FDCS, these cells grow out of control and form a tumor. Most often the tumor shows up as a lump that grows slowly and does not hurt, frequently in a lymph node in the neck. It can also start outside the lymph nodes, in places such as the abdomen, liver, spleen, chest or throat. A tumor deep in the body may cause no symptoms until it is large enough to press on nearby organs, which can lead to pain, a feeling of fullness or trouble swallowing or breathing, depending on where it is. FDCS is usually considered a low- to intermediate-grade cancer, meaning it tends to grow more slowly than many aggressive cancers. Even so, it can come back after treatment and sometimes spreads, so it is treated as a true cancer rather than a benign growth.
In most people, the cause of FDCS is unknown, and there is no known way to prevent it. It occurs mainly in adults, typically in middle age, and does not appear to favor men or women. Two associations are recognized. Some cases of the classic form develop alongside or after Castleman disease, a non-cancerous overgrowth of lymph node tissue, which researchers think may sometimes be an earlier step toward FDCS. A separate inflammatory form, which usually arises in the liver or spleen, is consistently linked to Epstein-Barr virus (EBV), the common virus that causes mononucleosis. Having had EBV, as most adults have, does not mean someone is likely to develop FDCS. FDCS is also more often accompanied by autoimmune conditions than would be expected by chance. In one large center's experience, about 1 in 5 patients had one, most often a blistering disease called paraneoplastic pemphigus or the muscle-weakness disorder myasthenia gravis. These seem to be triggered by the tumor rather than causing it.
FDCS is diagnosed by examining tissue from the tumor, usually after a doctor finds a lump or a scan shows a mass. A biopsy takes a sample with a needle or removes the lump surgically, and in some cases the diagnosis is only made once the whole tumor has been removed. Under the microscope, FDCS can look very much like other tumors, including lymphoma, other sarcomas, carcinoma and melanoma. Depending on where the tumor is, published reports suggest a substantial share of cases are first misdiagnosed. To confirm FDCS, a pathologist uses special stains (immunohistochemistry) that detect proteins typical of follicular dendritic cells, such as CD21, CD23 and CD35. Because the tumor is rare, review by a pathologist experienced with lymph node or sarcoma pathology is often helpful. Once FDCS is confirmed, imaging such as CT or PET-CT scans shows the size of the tumor and whether it has spread to other lymph nodes or organs such as the lungs or liver. This staging guides treatment planning.
Because FDCS is so rare, there are no clinical trials comparing treatments, and care is based on case series and registry data. Treatment is usually planned by a cancer team that may include a surgeon, a medical oncologist and a radiation oncologist. Surgery to remove the entire tumor is the main treatment when it is possible, and people whose tumor is completely removed tend to do best. The operation depends on where the tumor is, ranging from removal of a lymph node in the neck to surgery on an abdominal organ. Radiation therapy is sometimes given to the area after surgery to lower the chance of the tumor returning in the same place, particularly when the tumor was large or not removed with clear edges. One large center found fewer local recurrences with this approach, but other studies have not shown that it helps people live longer, so the decision is individual. Chemotherapy is used mainly when the tumor cannot be removed or has spread. Combinations that have been used include gemcitabine with docetaxel and regimens borrowed from lymphoma treatment, such as the four-drug combination known as CHOP. In a small series, gemcitabine with a taxane shrank the tumor in most patients, though responses often lasted around a year. Treatments given after a relapse work less often. Immunotherapy and targeted drugs have helped some individual patients, but their role is still being studied, and a clinical trial may be worth asking about.
The outlook for FDCS varies widely. A small, localized tumor in a lymph node that is completely removed can be cured or stay away for many years, while tumors that are large, located in the abdomen or chest, or have spread are harder to control. In a US cancer registry study of 187 people, about 60% were alive five years after diagnosis. Being over 60, having spread disease, and tumors in chest organs were linked to shorter survival. These figures describe groups, not any one person. The tumor comes back in a substantial share of people, often in the same area where it started and sometimes years later. For that reason, follow-up usually continues for the long term, with regular examinations and scans. When it does return, further surgery, radiation or other drugs may be options. Recovery from treatment depends on what was done. Removal of a single lymph node usually means a short recovery, while abdominal surgery, a course of radiation or chemotherapy can affect energy, eating and work for weeks to months. If an associated autoimmune condition develops, it may need its own specialist care alongside cancer follow-up.
See a doctor about any lump in the neck, armpit or groin, or anywhere else, that keeps growing or does not go away, even if it is painless. A scan that shows an unexplained mass also deserves a clear diagnosis rather than watchful waiting. If you have been treated for FDCS, tell your care team about a new lump, swelling near the original site or new symptoms such as pain or pressure, even before your next scheduled visit. Contact your care team promptly about painful mouth sores that do not heal, a blistering skin rash or sore red eyes, which can be signs of paraneoplastic pemphigus, an autoimmune condition linked to this tumor. New or worsening shortness of breath also needs prompt attention, since that condition can damage the small airways of the lungs.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Follicular Dendritic Cell Sarcoma is like, what's helped you, or ask the community a question.